Plasma and Tissue Depletion of Florfenicol and Florfenicol-amine in Chickens

被引:86
作者
Anadon, Arturo [1 ]
Aranzazu Martinez, Maria [1 ]
Martinez, Marta [1 ]
Rios, Alba [1 ]
Caballero, Virginia [1 ]
Ares, Irma [1 ]
Rosa Martinez-Larranaga, Maria [1 ]
机构
[1] Univ Complutense Madrid, Dept Pharmacol & Toxicol, Fac Vet Med, E-28040 Madrid, Spain
关键词
Florfenicol; plasma and tissue depletion; withdrawal time; chickens for fattening;
D O I
10.1021/jf802138y
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
Chickens were used to investigate plasma disposition of florfenicol after single intravenous (i.v.) and oral dose (20 mg kg(-1) body weight) and to study residue depletion of florfenicol and its major metabolite florfenicol-amine, after multiple oral doses (40 mg kg(-1) body weight, daily for 3 days). Plasma and tissue samples were analyzed using a high-performance liquid chromatography (HPLC) method. After i.v. and oral administration, plasma concentration-time curves were best described by a two-compartment open model. The mean [standard deviation (SD)] elimination half-life (t(1)/(2)beta) of florfenicol in plasma was 7.90 +/- 0.48 and 8.34 +/- 0.64 h after i.v. and oral administration, respectively. The maximum plasma concentration was 10.23 +/- 1.67 mu g mL(-1), and the interval from oral administration until maximal concentration was 0.63 mu 0.07 h. Oral bioavailability was found to be 87 16%. Florfenicol was converted to florfenicol-amine. After multiple oral dose (40 mg kg-1 body weight, daily for 3 days), in kidney and liver, concentrations of florfenicol (1119.34 +/- 31.81 and 817.34 +/- 91.65 mu g kg(-1), respectively) and florfenicol-amine (60.67 +/- 13.05 and 48.50 +/- 13.07 mu g kg(-1), respectively) persisted for 7 days. The prolonged presence of residues of florfenicoi and florfenicol-amine in edible tissues can play an important role in human food safety, because the compounds could give rise to a possible health risk. A withdrawal time of 6 days was necessary to ensure that the residues of florfenicol were less than the maximal residue limits or tolerance established by the European Union.
引用
收藏
页码:11049 / 11056
页数:8
相关论文
共 46 条
[11]   THE INVITRO SUSCEPTIBILITY OF AEROMONAS-SALMONICIDA AND OTHER FISH-PATHOGENIC BACTERIA TO 29 ANTIMICROBIAL AGENTS [J].
INGLIS, V ;
RICHARDS, RH .
JOURNAL OF FISH DISEASES, 1991, 14 (06) :641-650
[12]   Pharmacokinetics of florfenicol in pigs following intravenous, intramuscular or oral administration and the effects of feed intake on oral dosing [J].
Jiang, HX ;
Zeng, ZL ;
Chen, ZL ;
Liu, JJ ;
Fung, KF .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2006, 29 (02) :153-156
[13]   Bioavailability and pharmacokinetics of florfenicol in healthy sheep [J].
Jianzhong, S ;
Xiubo, L ;
Haiyang, J ;
Walter, HH .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2004, 27 (03) :163-168
[14]   Intravenous and subcutaneous pharmacokinetics of florfenicol in sheep [J].
Lane, VM ;
Wetzlich, S ;
Clifford, A ;
Taylor, I ;
Craigmill, AL ;
Villarroel, A .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2004, 27 (04) :191-196
[15]  
Lavy E., 1991, Acta Veterinaria Scandinavica, P133
[16]   Rational dosing of antimicrobial drugs: animals versus humans [J].
Lees, P ;
Aliabadi, FS .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :269-284
[17]   Pharmacokinetics of florfenicol in healthy pigs and in pigs experimentally infected with Actinobacillus pleuropneumoniae [J].
Liu, JZ ;
Fung, KF ;
Chen, ZL ;
Zeng, ZL ;
Zhang, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) :820-823
[18]   PHARMACOKINETICS OF FLORFENICOL FOLLOWING INTRAVENOUS AND INTRAMUSCULAR DOSES TO CATTLE [J].
LOBELL, RD ;
VARMA, KJ ;
JOHNSON, JC ;
SAMS, RA ;
GERKEN, DF ;
ASHCRAFT, SM .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1994, 17 (04) :253-258
[19]   Nitrogen fertilization using hydroponic cultures to fertigate ornamental shrubs [J].
Martín, I ;
Alonso, N ;
López, MC ;
Prieto, M ;
Cadahía, C ;
Eymar, E .
JOURNAL OF PLANT NUTRITION, 2006, 29 (01) :1-23
[20]  
Martinez-Larranaga M. R., 2003, Journal of Veterinary Pharmacology and Therapeutics, V26, P115